-
representations are developed. In particular, the project will support designers to achieve driver and passenger experiences that surpass current best-in-class benchmarks. Beyond the automotive sector, the project
-
small molecule interactions with DNA, RNA and associated proteins. We are exploiting our findings from such methods to design bifunctional small molecules that target the genome and chromatin-associated
-
, including Chemistry, Physics, Materials, and Engineering. Shortlisting is based on written applications (qualifications, aspirations, experience), with final selection via interview focusing on independent
-
and Technology (CST) at the University of Cambridge. The goal of this PhD programme is to launch one "deceptive by design" project that combines the perspectives of human-computer interaction (HCI) and
-
the combined themes of human-computer interaction and critical computing. The lab will be exploring the notion of "deceptive by design" on all fronts: social identity cues in the design of LLM-based chatbots
-
, research integrity, and ethical experimental design. Regular seminars, workshops, and mentoring across Cambridge and AstraZeneca will provide exposure to drug discovery pipelines and translational science
-
tumours and metastases with the goal to design combinatorial therapeutic approaches. The project will involve the use of genetically complex organoid-derived transplantation mouse models of pancreatic
-
dispersion - and develop a system to disperse the particles. The project will explore the options for dispersion and the options for nozzle design and whether substantial additional air supply is needed
-
, qualifications and experience required to perform the role will include a good working knowledge of fluidization, fluid mechanics and compressible flow and an interest in practical design and experimentation. It
-
of our approach is the innovation of novel methods to investigate genome function. For example, we have recently developed ways to map the binding of nucleic acid-interacting drugs and small molecules